🇺🇸 FDA
Pipeline program

HRS-6213

HRS-6213-101

Phase 2 small_molecule active

Quick answer

HRS-6213 for Patients With Solid Tumors is a Phase 2 program (small_molecule) at Jian Li with 1 ClinicalTrials.gov record(s).

Program details

Company
Jian Li
Indication
Patients With Solid Tumors
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials